Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model
Brain damage was identified as the most consistent factor limiting the patient's probability for improvements from the earliest stages and across the whole course of MS. Protecting brain integrity early in MS should have greater weight in clinical decision-making.
Authors
- Robert A Bermel (ORCID: https://orcid.org/0000-0003-2334-6883)
- Stephen Gardiner (ORCID: https://orcid.org/0000-0002-5157-1087)
- Marie‐Catherine Mousseau (ORCID: https://orcid.org/0009-0006-7091-7019)
- Jelena Čuklina (ORCID: https://orcid.org/0000-0002-3837-9349)
- Heinz Wiendl (ORCID: https://orcid.org/0000-0003-4310-3432)
- Samantha C. Pendleton (ORCID: https://orcid.org/0000-0002-6169-0135)
- Wendy Su
- Habib Ganjgahi (ORCID: https://orcid.org/0000-0002-7332-9478)
- Piet Aarden (ORCID: https://orcid.org/0000-0001-7826-7985)
- Thomas E. Nichols (ORCID: https://orcid.org/0000-0002-4516-5103)
- Douglas Lorne Arnold (ORCID: https://orcid.org/0000-0003-4266-0106)
- Alex Ocampo (ORCID: https://orcid.org/0000-0003-1967-039X)
- Dieter A. Häring (ORCID: https://orcid.org/0000-0001-5690-8710)
- Farhad Hatami (ORCID: https://orcid.org/0000-0002-0275-9243)
- Yang Sun
- Bernd C. Kieseier
- Gordon Graham
Institutions
- Novartis (Switzerland) (CH)
- Montreal Neurological Institute and Hospital (CA)
- The University of Sydney (AU)
- Cleveland Clinic (US)
- University of Oxford (GB)
- University Hospital Münster (DE)
- Novartis (United States) (US)
- Novartis (Ireland) (IE)
- McGill University (CA)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1177/13524585241275471
- Citations
- 2
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Novartis Pharma